Nirmatrelvir-ritonavir: Difference between revisions
From IDWiki
(Created page with "== Dosing == * COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset Category:Medications") |
No edit summary |
||
| Line 2: | Line 2: | ||
* COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset |
* COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset |
||
| + | |||
| + | === Renal Dosing === |
||
| + | |||
| + | * eGFR ≥60 mL/min: no adjustment |
||
| + | * eGFR 30-59 mL/min: nirmetrelvir/ritonavir 150 mg/100 mg p.o. bid |
||
| + | * eGFR <30 mL/min: not recommended |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Revision as of 10:02, 18 January 2022
Dosing
- COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset
Renal Dosing
- eGFR ≥60 mL/min: no adjustment
- eGFR 30-59 mL/min: nirmetrelvir/ritonavir 150 mg/100 mg p.o. bid
- eGFR <30 mL/min: not recommended
